This page shows you the latest news items in this category. This is page number 16.

Total 251735 results found since Jan 2013.

Survival Rates of Breast Cancer Patients Aged 40 to 49 Years according to Detection Modality in Korea: Screening Ultrasound versus Mammography.
CONCLUSION: Our study found that Korean females aged 40-49 years with US-detected breast cancer showed better DFS than those with mammography-detected breast cancer. However, there were no statistically significant differences in OS. PMID: 32901456 [PubMed - as supplied by publisher]
Source: Korean Journal of Radiology - September 11, 2020 Category: Radiology Tags: Korean J Radiol Source Type: research

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
Triple negative breast cancer (TNBC) remains the most challenging breast cancer subtype so far. Specific therapeutic approaches have rarely achieved clinical improvements in treatment of TNBC patients and effe...
Source: Molecular Cancer - September 11, 2020 Category: Cancer & Oncology Authors: Jie Li, Maoguang Ma, Xuesong Yang, Maolei Zhang, Jingyan Luo, Huangkai Zhou, Nunu Huang, Feizhe Xiao, Bingquan Lai, Weiming Lv and Nu Zhang Tags: Research Source Type: research

Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold
Kang and colleagues evaluated on a case series of 1848 breast cancer (BC) patients operated for a first primary ER positive HER2 negative BC if Ki67 expression is a significant prognostic factor only when PgR ...
Source: Diagnostic Pathology - September 11, 2020 Category: Pathology Authors: Roberta Maltoni, Michela Palleschi, Sara Ravaioli, Maria Maddalena Tumedei, Mattia Altini and Sara Bravaccini Tags: Commentary Source Type: research

Efficacy analysis of intraoperative radiotherapy in patients with early-stage breast cancer
To analyze the clinical efficacy of intraoperative radiotherapy (IORT) after breast-conserving surgery (BCS) in patients with early-stage breast cancer (BC), and to investigate the relationship between its inf...
Source: Cancer Cell International - September 11, 2020 Category: Cancer & Oncology Authors: Lin Wang, Minmin Zhu, Yuelong Cui, Xudong Zhang and Guowen Li Tags: Primary research Source Type: research

Practical update for the use of bone-targeted agents in patients with bone metastases from metastatic breast cancer or castration-resistant prostate cancer.
Authors: Southcott D, Awan A, Ghate K, Clemons M, Fernandes R Abstract Bone metastases are a significant source of morbidity and mortality for patients with breast and prostate cancer. In this review, we discuss key practical themes regarding the use of bone-targeted agents (btas) such as bisphosphonates and denosumab for managing bony metastatic disease. The btas both delay the onset and reduce the incidence of skeletal-related events (sres), defined as any or all of a need for radiation therapy or surgery to bone, pathologic fracture, spinal cord compression, or hypercalcemia of malignancy. They have more modest ...
Source: Current Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Breast cancer diagnosis and treatment wait times in specialized diagnostic units compared with usual care: a population-based study.
Conclusions: Diagnosis of bca through a bas was associated with a shorter diagnostic interval, but a longer treatment interval. Although efficiencies in the diagnostic interval might help to reduce distress experienced by patients, the longer treatment intervals for patients who are bas-diagnosed remain a cause for concern. PMID: 32905256 [PubMed - as supplied by publisher]
Source: Current Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

The case for breast-conservation treatment rates to be a quality metric.
Authors: Tan MP, Silva E PMID: 32905204 [PubMed - as supplied by publisher]
Source: Current Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells.
Authors: Wei C, Li X Abstract Breast cancer is one of the most aggressive malignant tumors in women. According to the expression differences of estrogen receptor, progesterone receptor, human epidermal growth factor receptor‑2 (HER‑2) and cell proliferation antigen Ki‑67, breast cancer can be divided into four molecular subtypes: Luminal A, Luminal B, HER‑2 overexpression and Basal‑like. Yes‑associated protein (YAP), a downstream effector of the Hippo pathway, is overexpressed in human cancers and is associated with proliferation, apoptosis, migration, invasion and resistance to chemotherapy drugs in br...
Source: Molecular Medicine Reports - September 11, 2020 Category: Molecular Biology Tags: Mol Med Rep Source Type: research

Combined expression levels of KDM2A and KDM2B correlate with nucleolar size and prognosis in primary breast carcinomas.
In this study we aimed to define the combined contribution of KDM2A and KDM2B to breast cancer outcome. KDM2A and KDM2B mRNA levels, nucleolar area as a marker of ribosome biogenesis, and patients' prognosis were retrospectively assessed in a series of primary breast carcinomas. We observed that tumors characterized by reduced levels of both KDM2A and KDM2B displayed a particularly aggressive clinical behavior and increased nucleolar size. Our results suggest that KDM2A and KDM2B may cooperate in regulating ribosome biogenesis thus influencing the biological behavior and clinical outcome of human breast cancers. PMID: ...
Source: Histology and Histopathology - September 11, 2020 Category: Cytology Tags: Histol Histopathol Source Type: research

Cancers, Vol. 12, Pages 2595: New Insights into Breast and Endometrial Cancers
i Cancers of the breast and endometrium are some of the most common cancers affecting women [...]
Source: Cancers - September 11, 2020 Category: Cancer & Oncology Authors: Yasuhiro Miki Tags: Editorial Source Type: research

Breast Sensation Satisfaction after Reconstruction and the Implications of Nerve Coaptation for Preoperative Counseling
This article appropriately emphasized the importance of self-esteem and sexual function related to breast intimacy after breast cancer surgery, both with and without r econstruction. They concluded that compared with patients who had undergone nipple-sparing mastectomy (NSM) with reconstruction, patients who had undergone breast-conserving therapy (BCT) reported significantly higher rates of satisfaction being seen undressed, breast-related sexual intimacy, and po stoperative pleasurable breast caress, and made references to the issue of breast hypoesthesia often experienced after mastectomy.
Source: Journal of the American College of Surgeons - September 11, 2020 Category: Surgery Authors: Dani C. Inglesby, Peter W. Henderson, Minas Chrysopoulo Tags: Letter Source Type: research

NTCP model for hypothyroidism after supraclavicular-directed radiation therapy for breast cancer.
CONCLUSION: NTCP modeling within our patient cohort suggested that greater than 8.5 cc thyroid volume receiving less than 20 Gy may be a recommended dosimetric guideline to minimize HT risk in breast cancer patients receiving SCV-directed RT. PMID: 32926911 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - September 11, 2020 Category: Radiology Authors: Huang H, Roberson J, Hou W, Mani K, Valentine E, Ryu S, Stessin A Tags: Radiother Oncol Source Type: research

A randomized control trial of meditation compared to music listening to improve cognitive function for breast cancer survivors: Feasibility and acceptability.
CONCLUSION: KK and ML are feasible, acceptable, and cost-effective interventions that may be beneficial for survivors' cognition and psychological symptoms. Both interventions were easy to learn, low cost, and required just 12 min/day. Meditation or music listening could offer providers evidence-based suggestions to BCS experiencing cognitive symptoms. CLINICAL TRIALS REGISTRATION NUMBER: NCT03696056. PMID: 32949954 [PubMed - as supplied by publisher]
Source: Complementary Therapies in Clinical Practice - September 11, 2020 Category: Complementary Medicine Authors: Henneghan AM, Becker H, Harrison ML, Inselmann K, Fico B, Schafer H, King E, Patt D, Kesler S Tags: Complement Ther Clin Pract Source Type: research

A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer
Conclusion: The F2P Score reported herein, integrating the clinicopathological and genomic variables, may inform prognosis and endocrine responsiveness. After the benefits and risks have been considered, treatment escalation may be an alternative strategy for patients with a higher score.
Source: Frontiers in Oncology - September 11, 2020 Category: Cancer & Oncology Source Type: research

Chloride intracellular channel protein 2: prognostic marker and correlation with PD-1/PD-L1 in breast cancer.
Abstract Immune checkpoint inhibition has emerged as an effective treatment for multiple solid tumors, including advanced-stage breast cancer (BC). During the past decade, the US Food and Drug Administration has approved a number of agents for immune checkpoint blockade (ICB). However, the limited data on monotherapy anti-tumor activity in BC underscores the need for robust predictive biomarker development. Here, we used weighted gene coexpression network analysis of genes differentially expressed between BC and normal tissue to identify genes coexpressed with programmed death-1 (PD-1) and its ligand (PD-L1). Tumo...
Source: Aging - September 11, 2020 Category: Biomedical Science Authors: Xu T, Wang Z, Dong M, Wu D, Liao S, Li X Tags: Aging (Albany NY) Source Type: research

The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study
This study aimed to assess a potential causal relationship between genetic variants associated with plasma lipid traits (high-density lipoprotein, HDL; low-density lipoprotein, LDL; triglycerides, TGs) with risk for BC using Mendelian randomization (MR). Methods and findingsData from genome-wide association studies in up to 215,551 participants from the Million Veteran Program (MVP) were used to construct genetic instruments for plasma lipid traits. The effect of these instruments on BC risk was evaluated using genetic data from the BCAC (Breast Cancer Association Consortium) based on 122,977 BC cases and 105,974 controls....
Source: PLoS Medicine - September 11, 2020 Category: Internal Medicine Authors: Kelsey E. Johnson Source Type: research

Predicting Survival Benefit of Sparing Sentinel Lymph Node Biopsy in Low-Risk Elderly Patients With Early Breast Cancer: A Population-Based Analysis
Conclusion: Well-validated nomograms and a risk stratification model were constructed to evaluate survival benefit from SLNB in elderly patients with early-stage breast cancer. SLNB was important for patients in the high-risk group but could be omitted in the low-risk group without sacrificing survival. This study could assist clinicians and elderly patients to weigh the risk–benefit of SLNB and make individualized decisions. We look forward to more powerful evidence from prospective trials.
Source: Frontiers in Oncology - September 11, 2020 Category: Cancer & Oncology Source Type: research

Erector spinae plane block versus retrolaminar block for postoperative analgesia after breast surgery: a randomized controlled trial
ConclusionESPB is equivalent, and not superior, to RLB for postoperative analgesia after breast surgery when 20  mL of 0.375% levobupivacaine is injected at the fourth thoracic vertebra.
Source: Journal of Anesthesia - September 11, 2020 Category: Anesthesiology Source Type: research

QT Ultrasound to bring breast ultrasound system to China
Ultrasound technology developer QT Ultrasound has partnered with Shanghai-based...Read more on AuntMinnie.comRelated Reading: QT Ultrasound touts presentations on 3D ultrasound QT Ultrasound opens Ariz. center QT Ultrasound creates 3D-printed breast tissue using US QT Ultrasound touts new clinical studies QT Ultrasound launches commercial scanning centers
Source: AuntMinnie.com Headlines - September 10, 2020 Category: Radiology Source Type: news

New | phs001870.v1.p1 | Genomic Changes in Breast Cancer Among Chinese Women in Hong Kong
Genomic Changes in Breast Cancer Among Chinese Women in Hong Kong  (study page |release notes)
Source: dbGaP, the database of Genotypes and Phenotypes - September 10, 2020 Category: Genetics & Stem Cells Tags: StudyRelease Source Type: research

Gene Testing for Patients With Breast Cancer and Second Cancer Gene Testing for Patients With Breast Cancer and Second Cancer
All breast cancer patients who develop a 2nd primary cancer should undergo multigene panel testing. The authors note that women with breast cancer have a 4%-16% lifetime risk of a second primary cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - September 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

6 Gy x 5 Fraction External-Beam Accelerated Partial Breast Irradiation (APBI) using IMRT Results in Superior Patient-Reported Cosmetic Outcomes Compared to 3DCRT
There have been several validated regimens of accelerated partial breast irradiation (APBI) for early-stage breast cancer, but the optimal approach especially as it relates to cosmetic outcome is uncertain. A 30 Gy in 5 fraction external-beam partial breast approach has been shown to be an effective regimen with improved cosmesis compared to conventional whole-breast radiotherapy in a randomized trial, although this was limited to use with IMRT.
Source: International Journal of Radiation Oncology * Biology * Physics - September 10, 2020 Category: Radiology Authors: Nima Harandi, Roy Abendroth, John Lee Source Type: research

Clinical Outcomes of Breast Brain Metastases by Subtype following LINAC Based Stereotactic Radiation
Management of breast cancer brain metastases has become an increasing concern due to improved systemic control. Failure patterns in the brain may vary by breast cancer subtype.
Source: International Journal of Radiation Oncology * Biology * Physics - September 10, 2020 Category: Radiology Authors: Matthew Mills, Chetna Thawani, Nicholas Figura, Siriporn Sarangkasiri, Iman Washington, Timothy Robinson, Roberto Diaz, Arnold Etame, Michael Vogelbaum, Hsiang-Hsuan Michael Yu, Kamran Ahmed Source Type: research

Long-term Risk of Fatal Heart Disease Among Breast Cancer Patients
In breast cancer patients, receipt of radiotherapy and chemotherapy may increase the risk of heart disease.
Source: International Journal of Radiation Oncology * Biology * Physics - September 10, 2020 Category: Radiology Authors: Nicholas Zaorsky, Aya Agha, Samantha Horn, Jennifer Rosenberg, Daniel Trifiletti, Roberto Diaz, Alexander Louie Source Type: research

Outcomes Among Hormone Receptor Positive Metastatic Inflammatory Breast Cancer (IBC)
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, accounting for only 1-5% of breast cancer diagnoses but up to 10% of breast cancer deaths annually in the United States. In contrast to findings in non-IBC patients, prior studies of stage III IBC patients suggest that compared to other receptor subtypes, hormone receptor (HR) positivity is not a favorable prognostic factor.
Source: International Journal of Radiation Oncology * Biology * Physics - September 10, 2020 Category: Radiology Authors: Wendy Woodward, Renae Van Wyhe, Rebecca Tidwell, Michael Stauder, Bora Lim, Mediget Teshome, Savitri Krishnamurthy, Huong Le-Petross, Naoto Ueno Source Type: research

Management of Regional Nodes in the Treatment of Breast Cancer: An American Radium Society Appropriate Us Criteria Panel for Breast Cancer Systematic Review and Guideline
The management of regional nodes in breast cancer patients is a complex and evolving area of significant clinical impact. Numerous recent randomized trials and other studies have reported improved survival outcomes associated with the inclusion of regional nodal irradiation in patients with node positive breast cancer or even high risk node negative breast cancer. The selection of patients for extent of axillary surgery has also been the subject of numerous randomized trials with a resulting reduction in the use of axillary dissection in many populations.
Source: International Journal of Radiation Oncology * Biology * Physics - September 10, 2020 Category: Radiology Authors: Eleanor Harris, Eleanor Walker, Manjeet Chadha Source Type: research

Five Day Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT) in Stage 0-II Breast Cancer: A Report of 114 Patients with up to 2 Year Follow-up
Randomized trials in selected early stage breast cancer patients with up to 10 year follow-up have proven that Accelerated Partial Breast Irradiation (APBI) given via High Dose Rate (HDR) implant bid in 5 days is equivalent to whole breast External Radiation Therapy (XRT) given qd in 5-6 weeks in regard to breast tumor local recurrence (LR) [1-2]. However, complications with APBI implant in a Medicare database review have been significant, with 3.95% of women requiring Mastectomy, 16.2% developing infections, and another 16.3% experiencing non-infection complications including rib fractures, fat necrosis, and breast pain [3].
Source: International Journal of Radiation Oncology * Biology * Physics - September 10, 2020 Category: Radiology Authors: Rufus Mark, Valerie Gorman, Steven McCoullough Source Type: research

Radiation and Gold Nanoparticle Increase the Expression of Immunogenic Cell Death Markers in MDA MB 231 Breast Cancer Model
Tumor immunogenic cell death (ICD) plays a major role in stimulating host anti-cancer immune response that can determine the success of cancer radiotherapy (RT). Additionally, ICD can also be induced by radiation itself. The main feature of ICD is the release of immunogenic molecules by dying cells, termed damage associated molecular patterns (DAMPs) that act on innate and adaptive immune components to induce long-lasting antitumor immunity. Two breast cancer (BCa) DAMPs involved in phagocytosis and dendritic cell antigen presentation are Calreticulin (CLR) and HMGB1; loss of HMGB1 expression is linked to poor clinical prognosis.
Source: International Journal of Radiation Oncology * Biology * Physics - September 10, 2020 Category: Radiology Authors: Branislava Janic, Stephen Brown, Ryan Neff, Fangchao Liu, Kevin Bobbitt, Guangzhao Mao, Indrin Chetty, Benjamin Movsas, Ning Wen Source Type: research

Comparing Survival Differences Between Breast-Conserving Therapy and Mastectomy in Patients with Early-Stage Breast Cancer
In 1990 breast-conserving therapy (BCT) was recommended as a preferred treatment for early-stage breast cancer by the NIH consensus statement based on randomized trials demonstrating BCT to have equivalent survival outcomes as mastectomy for early-stage breast cancer patients. BCT became more common while total mastectomy (TM) rates decreased. More recently, patients with early-stage breast cancer are undergoing TM with increasing frequency. In light of increasing TM rates and given significant changes in radiation, surgery and systemic therapies, several groups have examined long-term outcomes for patients undergoing TM vs BCT.
Source: International Journal of Radiation Oncology * Biology * Physics - September 10, 2020 Category: Radiology Authors: Min Yi, Benjamin Smith, Mariana Chavez Mac Gregor, Abigail Caudle, Sarah DeSnyder, Henry Kuerer, Kelly Hunt Source Type: research

The Gender of Radiation Oncologists Treating Breast and Genitourinary Cancers at US Comprehensive Cancer Centers
The vast amount of knowledge required to provide state-of-the art Radiation Oncology care for every cancer inherently results in subspecialization based on anatomic site of interest, most prominently in the academic setting. Certain subspecialties within Radiation Oncology are dominated by patients of a particular gender, with two of the most common being breast cancer and genitourinary cancer.
Source: International Journal of Radiation Oncology * Biology * Physics - September 10, 2020 Category: Radiology Authors: Shearwood McClelland, Christina Huang, Reshma Jagsi, Richard Zellars Source Type: research

CARA Treatment Pilot Study for Breast Positioning
Conditions:   Breast Cancer;   Side Effect Intervention:   Device: CARA - carbon fibre adjustable re-usable accessory for breast positioning Sponsors:   British Columbia Cancer Agency;   Canadian Cancer Society Research Institute (CCSRI) Completed
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Condition:   Breast Neoplasms Interventions:   Drug: Alpelisib;   Drug: Fulvestrant;   Drug: Placebo Sponsor:   Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

Maxillary Sinus Floor Augmentation in Diabetic Patients
Conditions:   Jaw, Edentulous, Partially;   Diabetes Intervention:   Procedure: Sinus floor augmentation Sponsors:   University of Copenhagen;   Copenhagen University Hospital at Herlev;   Aalborg University Hospital Not yet recruiting
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

CARA Treatment Pilot Study for Breast Positioning
Conditions:   Breast Cancer;   Side Effect Intervention:   Device: CARA - carbon fibre adjustable re-usable accessory for breast positioning Sponsors:   British Columbia Cancer Agency;   Canadian Cancer Society Research Institute (CCSRI) Completed
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Condition:   Breast Neoplasms Interventions:   Drug: Alpelisib;   Drug: Fulvestrant;   Drug: Placebo Sponsor:   Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

Taste Disorders and Their Relation to BMI, FFQ, and EORTC QLQ-BR23 in Breast Cancer Patients During Chemotherapy.
Conditions:   Breast Cancer;   Taste Disorders;   Dysgeusia;   Ageusia;   Quality of Life Intervention:   Other: Taste disorder´s test Sponsor:   Hospital General de Mexico Completed
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

Maxillary Sinus Floor Augmentation in Diabetic Patients
Conditions:   Jaw, Edentulous, Partially;   Diabetes Intervention:   Procedure: Sinus floor augmentation Sponsors:   University of Copenhagen;   Copenhagen University Hospital at Herlev;   Aalborg University Hospital Not yet recruiting
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Condition:   Breast Neoplasms Interventions:   Drug: Alpelisib;   Drug: Fulvestrant;   Drug: Placebo Sponsor:   Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

CARA Treatment Pilot Study for Breast Positioning
Conditions:   Breast Cancer;   Side Effect Intervention:   Device: CARA - carbon fibre adjustable re-usable accessory for breast positioning Sponsors:   British Columbia Cancer Agency;   Canadian Cancer Society Research Institute (CCSRI) Completed
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

Taste Disorders and Their Relation to BMI, FFQ, and EORTC QLQ-BR23 in Breast Cancer Patients During Chemotherapy.
Conditions:   Breast Cancer;   Taste Disorders;   Dysgeusia;   Ageusia;   Quality of Life Intervention:   Other: Taste disorder´s test Sponsor:   Hospital General de Mexico Completed
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

Maxillary Sinus Floor Augmentation in Diabetic Patients
Conditions:   Jaw, Edentulous, Partially;   Diabetes Intervention:   Procedure: Sinus floor augmentation Sponsors:   University of Copenhagen;   Copenhagen University Hospital at Herlev;   Aalborg University Hospital Not yet recruiting
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

CARA Treatment Pilot Study for Breast Positioning
Conditions:   Breast Cancer;   Side Effect Intervention:   Device: CARA - carbon fibre adjustable re-usable accessory for breast positioning Sponsors:   British Columbia Cancer Agency;   Canadian Cancer Society Research Institute (CCSRI) Completed
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

Maxillary Sinus Floor Augmentation in Diabetic Patients
Conditions:   Jaw, Edentulous, Partially;   Diabetes Intervention:   Procedure: Sinus floor augmentation Sponsors:   University of Copenhagen;   Copenhagen University Hospital at Herlev;   Aalborg University Hospital Not yet recruiting
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

Taste Disorders and Their Relation to BMI, FFQ, and EORTC QLQ-BR23 in Breast Cancer Patients During Chemotherapy.
Conditions:   Breast Cancer;   Taste Disorders;   Dysgeusia;   Ageusia;   Quality of Life Intervention:   Other: Taste disorder´s test Sponsor:   Hospital General de Mexico Completed
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Condition:   Breast Neoplasms Interventions:   Drug: Alpelisib;   Drug: Fulvestrant;   Drug: Placebo Sponsor:   Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - September 10, 2020 Category: Research Source Type: clinical trials